Brief: Everest Medicines Says Partner Calliditas Therapeutics Receives FDA Priority Review For Full Approval Of Nefecon
21/08/2023 01:36
Aug 20 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES ANNOUNCES PARTNER CALLIDITAS
THERAPEUTICS
RECEIVES FDA PRIORITY REVIEW FOR FULL APPROVAL OF NEFECON® FOR
THE TREATMENT OF IGA NEPHROPATHY
* PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE IS DEC.
20,
2023.
Source text for Eikon: ID:nPn7KV3v9a
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations